NCT00570700View on ClinicalTrials.gov

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Hormone-refractory Prostate CancerAdenocarcinoma of the ProstateHormone-resistant Prostate CancerProstate CancerRecurrent Prostate Cancer
Interventions
DRUG

Dasatinib

150mg (3 pills) orally daily for as long as the drug benefits

Trial Locations (6)

15232

University of Pittsburgh, Pittsburgh

29425

Medical University of South Carolina, and Hollings Cancer Network, Charleston

91010

City of Hope National Medical Center, Duarte

92354

Loma Linda University Cancer Center, Loma Linda

92868

Chao Family Comprehensive Cancer Center, Orange

St. Joseph Hospital, Orange

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of California, Irvine

OTHER

NCT00570700 - Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer | Biotech Hunter | Biotech Hunter